Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

@inproceedings{Marx2015DesignAB,
  title={Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)},
  author={Nikolaus Marx and Julio Rosenstock and Steven E Kahn and Bernard Zinman and John J. P. Kastelein and John M Lachin and Mark A. Espeland and Erich Bluhmki and Michaela Mattheus and Bart Ryckaert and Sanjay R. Patel and Odd Erik Johansen and Hans J Woerle},
  booktitle={Diabetes & vascular disease research},
  year={2015}
}
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin versus the sulphonylurea glimepiride. Eligible patients were sulphonylurea-naïve with HbA1c 6.5%-8.5% or previously exposed to sulphonylurea (in monotherapy or in a combination regimen <5 years… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?

Diabetes therapy : research, treatment and education of diabetes and related disorders • 2016
View 3 Excerpts
Highly Influenced

Cardiovascular effects of anti-diabetes drugs.

Expert opinion on drug safety • 2016
View 20 Excerpts
Highly Influenced

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Diabetes, metabolic syndrome and obesity : targets and therapy • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…